Action 18 | Paediatric HIV

top of page

AdobeStock_330370789 - 3.jpg

HIV TREATMENT

2020

Pharmaceutical companies, SRAs, WHO Prequalification Programme (PQ) and NRAs commit to:

Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.

Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.

Paediatric HIV & TB : Rome Action Plan

Action 18

Take all possible measures to rapidly complete development of priority paediatric drugs and formulations in the pipeline, with the goal of providing the maximum number of new formulations by end of 2018, especially for infants and young children.

Committed by:

Pharmaceutical companies

Sub-Actions & Milestones

Sub-action 18.1

Take all possible measures to rapidly complete development of priority paediatric drugs and formulations in the pipeline

Pharmceutical Companies

ViiV will be requesting a meeting with FDA early this summer to review development plans.

-

Milestone 18.1.1

-

-

-

-

Document (s)

-

-

-

-

Updates

Notes

Responsible

bottom of page